METHODS
Multicentric observational registry including 316 consecutive patients
who underwent catheter ablation for drug-resistant VT between January
2008 and July 2019. Primary and secondary efficacy endpoints were
defined as VT-free survival and all-cause death after ablation. Safety
outcomes were defined by 30-days mortality and procedure-related
complications.